Quarterly ResultApr 8, 2026, 07:11 AM
Regeneron Expects $102 Million Pre-Tax Acquired IPR&D Charge, Impacting Q1 2026 EPS by $0.81
AI Summary
Regeneron Pharmaceuticals anticipates an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis for the first quarter of 2026. This charge is primarily attributed to premiums on purchased equity securities, as well as development milestone and up-front payments related to recent collaboration and licensing agreements. The company expects this IPR&D charge to negatively impact both GAAP and non-GAAP net income per diluted share for Q1 2026 by approximately $0.81. Regeneron typically does not forecast such charges due to the inherent uncertainty regarding their future occurrence, magnitude, and timing.
Key Highlights
- Regeneron expects an acquired IPR&D charge of approximately $102 million on a pre-tax basis for the first quarter of 2026.
- The charge is primarily linked to premiums on equity securities purchased, along with development milestone and up-front payments from collaboration and licensing agreements.
- This IPR&D charge is projected to negatively impact both GAAP and non-GAAP net income per diluted share for Q1 2026 by approximately $0.81.
- Acquired IPR&D charges may include IPR&D from asset acquisitions, up-front payments, opt-in fees, certain development milestone payments, and premiums on equity securities related to collaboration and licensing agreements.
- Regeneron does not forecast these acquired IPR&D charges due to the uncertainty of their future occurrence, magnitude, and timing.
- The financial results for Q1 2026 are preliminary and subject to the company's financial statement closing procedures.